Creabilis Announces Headline Results of its Phase 2b Trial of Topical TrkA Kinase Inhibitor CT327

Creabilis awarded prestigious European Commission FP7 grant to further develop its LSE ‘topical-by-design’ technology

Creabilis appoints Catherine Moukheibir to its Board of Directors